Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platformFiled IND in ...

Truist analyst Joon Lee raised the firm’s price target on Corcept Therapeutics (CORT) to $150 from $76 and keeps a Buy rating on the shares.

A woman in the crowd during a recent Keith Urban performance was holding up a sign that read, "I beat cancer to hug Keith ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ('HBM' or the 'Company'; ...

OS Therapies ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its OST-HER2 listeria ...

OS Therapies Inc. ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial results ended ...

The firm previously said it will test the CER T-cell therapy CER-1236 in blood cancers after receiving FDA manufacturing clearance.

(Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced in addition to developing TH104 for the proposed ...

Proving causation is a challenge in healthcare, legal cases, and scientific research. How can professionals confirm that an ...

HONG KONG, March 31, 2025 /PRNewswire/ -- Guo Guangchang, Chairman of Fosun International Limited (HKEX: 0656), issued a letter to its shareholders on 30 March, outlining the Company's strategic ...

Even without visible rupture, silicone breast implants release particles that trigger an immune response and activate markers ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...